IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.856,32 +378,94 (+0,65%)
Amarin Corporation plc (AMRN)
Después del cierre:
Amarin Corporation plc
Iconic Offices, The Greenway
Block C Ardilaun Court St Stephens Green
Dublin 112-114
Ireland
353 0 166 99020
https://www.amarincorp.com
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 275
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Patrick J. Holt | President, CEO & Director | 678,88k | N/A | 1973 |
| Mr. Thomas Charles Reilly | Executive VP, CFO & Global Head of HR | 1,01M | N/A | 1973 |
| Dr. Steven B. Ketchum Ph.D. | Executive VP, President of Research & Development and Chief Scientific Officer | 1,16M | N/A | 1965 |
| Mr. Jonathan N. Provoost | Executive VP, Chief Legal & Compliance Officer and Secretary | 160,08k | N/A | 1970 |
| Mr. Aaron D. Berg | Executive VP & President of U.S. | 1,26M | N/A | 1963 |
| Mr. Jordan Zwick | Senior VP of Corporate Business Development & Investor Relations | N/A | N/A | 1987 |
| Mr. Laurent Abuaf | President of Europe & Senior VP | N/A | N/A | N/A |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs | N/A | N/A | N/A |
| Dr. David Keenan Ph.D. | Executive VP of Technical Operations & President of Europe | N/A | N/A | N/A |
Descripción
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Gobierno corporativo
El ISS Governance QualityScore de Amarin Corporation plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
